Immuneering recently announced positive initial Phase 2a data, including complete and partial responses, with IMM-1-104 in combination with chemotherapy in first-line pancreatic cancer patients - ...

(NASDAQ: KTTA), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor ... of PAS-004 in patients with MAPK pathway driven advanced solid tumors ...

The BRAFV600 mutation is found in about 50% of melanomas, and patients whose tumors harbor this mutation are often treated with MAPK inhibitors, which target the tumor's growth pathway.

Cancer growth blockers are also called cancer growth inhibitors. They are a type of targeted cancer drug. Our body makes chemicals called growth factors that control cell growth. Cancer growth ...

dahliae infection was elucidated by high-throughput sequencing technology. KEGG pathway analysis revealed that the upregulated genes in resistant cultivars were significantly enriched in the MAPK ...

The study also examined the MAPK (mitogen-activated protein kinase ... and increased susceptibility to protein degradation inhibitors. The research also established a comprehensive database ...

Effective induction of apoptosis can be achieved through inhibition or interference with Mcl-1. Thus, this mini review discusses existing Mcl-1 inhibitors. Figure 2. NSC260594 can regulate Mcl-1 ...

The Company aims to achieve universal activity through Deep Cyclic Inhibition of the MAPK pathway ... once-daily Deep Cyclic Inhibitor currently in a Phase 1/2a trial in patients with advanced ...

Expert Rev Resp Med. 2008;2(5):617-629. Binita Bhowmick, Medicines Evaluation Unit, The Langley Building, University Hospital of South Manchester NHS Trust, University of Manchester, Southmoor ...